Solving prostate problems

24 August 2018

The National Institute for Health and Care Excellence (NICE) has approved a new treatment for benign prostatic hyperplasia (BPH,) successfully helped to market by Southampton Science Park company Device Access.

BPH is the medical term for an enlarged prostate gland, a condition that affects as many as 50% of all men over the age of 50, and 60% of those over 60, in the UK. Non-cancerous, the condition can narrow or block the urethra (the tube that urine passes through to leave the body).

During this new procedure, heated water vapour is injected into the prostate using a probe that is passed up the urethra. The heat from the vapour destroys some of the prostate tissue, reducing its size and the dead cells are reabsorbed by the body. Minimally invasive, the treatment can be done under local anaesthetic in less than 20 minutes without an overnight hospital stay.

The innovation has been widely reported by the mainstream media including the BBC, ITV, the Daily Mail, the Times and the Telegraph amongst others.

Mike Branagan-Harris, CEO of Device Access said: “We are delighted that this treatment, which will help so many, has been given the green light by NICE. It gives clinicians an excellent alternative to offer patients. We have been working with the manufacturer since late 2015 in identifying key specialist centres to evaluate the technology. The first centre to perform the treatment was North Hampshire Hospital in Basingstoke with Urologist, Professor Richard Hindley. Our ultimate goal was to help them achieve this approval for NHS use from NICE. It is our 28th approval since I started Device Access in 2010.”

He continued: “Helping revolutionary medical technology treatments get to NHS patients faster is what we do all of the time. However, it’s not often that our stories achieve front page news. The interest in the treatment is testimony to the significance of its potential.”

Device Access helps medtech companies execute a successful market access strategy for the benefit of patients, NHS Hospitals and the Clinical Commissioning Groups.